Name: How your genetic data can help fight 'Long COVID’
Uploaded: 2021-04-27
Duration: 2 min 1 s
Description: Anne Wojcicki, CEO of 23andMe, dives into the details.

Anne Wojcicki, CEO of 23andMe, dives into the details. 

How your genetic data can help fight 'Long COVID’

Conferences

what are you learning about, you know, from your survey data about people with coded? Um, maybe there is a genetic component to people who have a long gestation with this disease. Absolute. Kobe is actually a really interesting example of how we've been able to leverage the 23 community. So in this instance when Covid hit last year, we realized that we had a role to play which was really in research. And we asked our customers whether or not they wanted to take a survey. So we put out a survey to our customers. And pretty quickly we got over a million people to take that survey. So if you think about part of the power of 23 m, we already have people who are engaged. They already have their genetic information and we already have information back where they've elected to tell us about their health background. So we could very quickly collect a lot of information about Covid. And what's most impressive to me is I had, you know, 60,000 plus people who had covid, but I had over a million people who did not have Covid who still took this survey. So we were actually able to, the publication has just come out. We were able to actually see that um that the o blood type looks protective against the acceptability and severity. And we have some other findings that we're also looking to now roll out. But we can very quickly do this type of analysis and then we can keep doing it. So, one of the things that I am hot for now is I have all these people, let's now start to study long coated. So how is it now that we can actually roll this kind of research into a long covid? So, again, part of what we tried to pioneer is this idea that people actually do want to participate in research. They're just not given an easy chance. And what we've done is like, we don't have all the startup costs of like starting a study, taking it down, starting to study. These people are just continuously engaged, and it's always a choice for people about whether or not they want to participate.